<italic style="font-style: italic">XRCC1</italic> gene DNA methylation on predicting the efficacy of oxaliplatin-based chemotherapy in patients with gastric cancer

Ping Wang; Mei Guo; Bing Wang; Henghua Zhou; Hua Yan

doi:10.13406/j.cnki.cyxb.003029

您当前的位置：

首页 >

文章列表页 >

XRCC1 gene DNA methylation on predicting the efficacy of oxaliplatin-based chemotherapy in patients with gastric cancer

Clinical research | 更新时间：2022-06-24

- XRCC1 gene DNA methylation on predicting the efficacy of oxaliplatin-based chemotherapy in patients with gastric cancer
- Journal of Shanxi Agricultural Sciences Vol. 47, Issue 5, Pages: 563-567(2022)
- 作者机构：
  
  1.上海交通大学医学院附属第九人民医院　消化内科，上海　200011
  2.上海交通大学医学院附属第九人民医院　普外科，上海　200011
  3.上海交通大学医学院附属第九人民医院　病理科，上海　200011
- 作者简介：
- 基金信息：
- DOI：10.13406/j.cnki.cyxb.003029
  CLC： R735.2
- Published：28 May 2022，
  
  Received：31 August 2021，
扫描看全文
Ping Wang, Mei Guo, Bing Wang, et al. XRCC1 gene DNA methylation on predicting the efficacy of oxaliplatin-based chemotherapy in patients with gastric cancer. [J]. Journal of Shanxi Agricultural Sciences 47(5):563-567(2022)
DOI：

Ping Wang, Mei Guo, Bing Wang, et al. XRCC1 gene DNA methylation on predicting the efficacy of oxaliplatin-based chemotherapy in patients with gastric cancer. [J]. Journal of Shanxi Agricultural Sciences 47(5):563-567(2022) DOI： 10.13406/j.cnki.cyxb.003029.

摘要

目的：

探讨

XRCC1

基因的DNA甲基化对接受含奥沙利铂方案辅助化疗胃癌患者的疗效预测价值。

方法：

经病理确诊的胃癌患者116例，接受奥沙利铂和氟尿嘧啶类联合的方案化疗至少6周期。采用亚硫酸氢盐测序法对胃癌手术标本进行

XRCC1

基因的甲基化水平检测，并分析其与胃癌患者化疗疗效的相关性。

结果：

不同性别、年龄、是否淋巴结转移、不同肿瘤直径、不同分化程度、是否接受辅助化疗的胃癌患者之间

XRCC1

基因的DNA甲基化水平差异均无统计学意义（

0.05）。术后接受化疗和未接受化疗的胃癌患者的平均生存期分别为（42.82±3.57）个月和（25.68±4.90）个月，接受化疗的胃癌患者生存期更长（

=7.208，

=0.07）。化疗有效组的平均甲基化率为51.60%，化疗无效组为38.31%，2组比较差异具有统计学意义（

0.05）。

结论：

XRCC1

基因的DNA甲基化率与奥沙利铂的敏感性呈正相关，是潜在的预测胃癌患者化疗有效性及预后的分子标记物。

Abstract

Objective

To investigate the value of

XRCC1

gene DNA methylation in predicting the efficacy of oxaliplatin-based adjuvant chemotherapy in patients with gastric cancer.

Methods

A total of 116 patients with gastric cancer received at least 6 cycles of combination chemotherapy of oxaliplatin and fluorouracil. Bisulfite sequencing was used to analyze the methylation of

XRCC1

gene in gastric cancer surgical specimens

and the correlation with the efficacy of chemotherapy in patients with gastric cancer were also analyzed.

Results

There was no statistically significant difference in the average methylation rates of

XRCC1

gene among gastric cancer patients with different gender

age

lymph node metastasis

tumor diameters

differentiation

and whether they received adjuvant chemotherapy (

0.05) . The average survival time of gastric cancer patients receiving chemotherapy and not receiving chemotherapy were (42.82±3.57) months and (25.68±4.90) months

respectively. The survival time of gastric cancer patients receiving chemotherapy was longer (

=7.208

=0.007) . The average methylation rate of chemotherapy effective group was 51.60%

and that of chemotherapy ineffective group was 38.31%

with significant differences between the two groups (

0.05) .

Conclusion

The DNA methylation rate of

XRCC1

gene is positively correlated with the sensitivity of oxaliplatin

which is a potential molecular marker to predict the efficacy and prognosis of chemotherapy in patients with gastric cancer.

关键词

胃肿瘤化学疗法辅助甲基化预后

Keywords

stomach neoplasmchemotherapyadjuvantmethylationprognosis

references

张思维, 杨之洵, 郑荣寿, 等. 2013年中国胃癌发病与死亡分析[J]. 中华肿瘤杂志, 2017, 39(7): 547-552.

Zhang SW, Yang ZX, Zheng RS, et al. Incidence and mortality of stomach cancer in China, 2013[J]. Chin J Oncol, 2017, 7(39): 547-552.

王少明, 郑荣寿, 张思维, 等. 2015年中国胃癌流行特征分析[J]. 中华流行病学杂志, 2019, 40(12): 1517-1521.

Wang SM, Zheng RS, Zhang SW, et al. Epidemiological characteristics of gastric cancer in China, 2015[J]. Chin J Epidemiol, 2019, 40(12): 1517-1521.

国家卫生健康委员会. 胃癌诊疗规范(2018年版)[J]. 中华消化病与影像杂志(电子版), 2019, 9(3): 118-144.

National Health Commission. Gastric Cancer Diagnosis and Treatment Standards (2018)[J]. J Dig Med Imageology Electron Ed, 2019, 9(3): 118-144.

Wagner AD, Syn NL, Moehler M, et al. Chemotherapy for advanced gastric cancer[J]. Cochrane Database Syst Rev, 2017, 8(8): CD004064.

Afifah NN, Diantini A, Intania R, et al. Genetic polymorphisms and the efficacy of platinum-based chemotherapy: review[J]. Pharmgenomics Pers Med, 2020, 13: 427-444.

Ortiz-Barahona V, Joshi RS, Esteller M. Use of DNA methylation profiling in translational oncology[J]. Semin Cancer Biol, 2020[Epub ahead of print]. doi: 10.1016/j.semcancer.2020.12.011http://doi.org/10.1016/j.semcancer.2020.12.011.

Uddin MS, Mamun AA, Alghamdi BS, et al. Epigenetics of glioblastoma multiforme: from molecular mechanisms to therapeutic approaches[J]. Semin Cancer Biol, 2020[Epub ahead of print]. doi: 10.1016/j.semcancer.2020.12.015http://doi.org/10.1016/j.semcancer.2020.12.015.

Brown R, Curry E, Magnani L, et al. Poised epigenetic states and acquired drug resistance in cancer[J]. Nat Rev Cancer, 2014, 14(11): 747-753.

中华人民共和国国家卫生和计划生育委员会. 胃癌规范化诊疗指南(试行)[J]. 中国医学前沿杂志(电子版), 2013, 5(8): 29-36.

State Health and Family Planning Commission of the people's Republic of China. Gastric Cancer Diagnosis and Treatment Standards (Trial)[J]. Chin J Front Med Sic Electron Version, 2013, 5(8): 29-36.

Galluzzi L, Senovilla L, Vitale I, et al. Molecular mechanisms of cisplatin resistance[J]. Oncogene, 2012, 31(15): 1869-1883.

Nagasubramanian R, Innocenti F, Ratain MJ. Pharmacogenetics in cancer treatment[J]. Annu Rev Med, 2003, 54: 437-452.

Fujii N. Potential strategies to target protein-protein interactions in the DNA damage response and repair pathways[J]. J Med Chem, 2017, 60(24): 9932-9959.

Wang P, Tang JT, Peng YS, et al. XRCC1 downregulated through promoter hypermethylation is involved in human gastric carcinogenesis[J]. J Dig Dis, 2010, 11(6): 343-351.

刘源. ERCC1、XRCC1表达对晚期NSCLC患者化疗疗效与预后的影响[J]. 实用癌症杂志, 2016, 31(9): 1396-1398.

Liu Y. Effects of ERCC1 and XRCC1 expression on the efficacy and prognosis of chemotherapy for advanced NSCLC[J]. Pract J Cancer, 2016, 31(9): 1396-1398.

Tudek B. Base excision repair modulation as a risk factor for human cancers[J]. Mol Aspects Med, 2007, 28(3/4): 258-275.

Zhao W, Hu LM, Xu JL, et al. Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced non-small cell lung cancer[J]. Cancer Chemother Pharmacol, 2013, 71(5): 1287-1295.

Lv HY, Li QC, Qiu WS, et al. Genetic polymorphism of XRCC1 correlated with response to oxaliplatin-based chemotherapy in advanced colorectal cancer[J]. Pathol Oncol Res, 2012, 18(4): 1009-1014.

Zhai XH, Huang J, Wu FX, et al. Impact of XRCC1, GSTP1, and GSTM1 polymorphisms on the survival of ovarian carcinoma patients treated with chemotherapy[J]. Oncol Res Treat, 2016, 39(7/8): 440-446.

Zhang Z, Xiang Q, Mu GY, et al. XRCC1 polymorphism and overall survival in ovarian cancer patients treated with platinum-based chemotherapy: a systematic review and MOOSE-compliant meta-analysis[J]. Medicine (Baltimore), 2018, 97(45): e12996.

Oleksiewicz U, Machnik M. Causes, effects, and clinical implications of perturbed patterns within the cancer epigenome[J]. Semin Cancer Biol, 2020[Epub ahead of print]. doi: 10.1016/j.semcancer.2020.12.014http://doi.org/10.1016/j.semcancer.2020.12.014.

Cheng Y, He C, Wang MN, et al. Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials[J]. Signal Transduct Target Ther, 2019, 4: 62.

Matei D, Fang F, Shen CY, et al. Epigenetic resensitization to platinum in ovarian cancer[J]. Cancer Res, 2012, 72(9): 2197-2205.

Yu SL, Ao Z, Wu Y, et al. ZNF300 promotes chemoresistance and aggressive behaviour in non-small-cell lung cancer[J]. Cell Prolif, 2020, 53(11): e12924.

Cervena K, Siskova A, Buchler T, et al. Methylation-based therapies for colorectal cancer[J]. Cells, 2020, 9(6): 1540.

Fazal Z, Singh R, Fang F, et al. Hypermethylation and global remodelling of DNA methylation is associated with acquired cisplatin resistance in testicular germ cell tumours[J]. Epigenetics, 2021, 16(10): 1071-1084.

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical results of chemotherapy applying docetaxel-cisplatin combination for advanced hormone independent prostate cancer

Anterior and posterior circulation infarction image score（APCIIS），a novel approach to evaluate the prognosis of patients with acute ischemic stroke

Diagnostic and prognostic value of muscle echogenicity combined with plasma inflammatory factors for intensive care unit-acquired weakness

Comparison of efficacy and complications of endoscopic surgery through three different approaches in the treatment of thyroid microcarcinoma

Related Author

Wang Ping

HE Wei-yang

et al

吴小候

王明

汤召兵

邓远忠

李杰

Related Institution

Department of Gastroenterology, Shanghai Ninth Peoples Hospital, Shanghai Jiao Tong University School of Medicine

Department of Urology,the First Affiliated Hospital,Chongqing Medical University

Department of Neurosurgery，The First Affiliated Hospital of Chongqing Medical University

Department of Ultrasound，Chongging Emergency Medical Center

Department of Neurology ， Chongging Emergency Medical Center

⁰

XRCC1 gene DNA methylation on predicting the efficacy of oxaliplatin-based chemotherapy in patients with gastric cancer

DOI：10.13406/j.cnki.cyxb.003029

摘要

Abstract

关键词

Keywords

references